Oh Kwang Kwon1, Ju Mi Jeon1, Eunji Sung1, Ann-Yea Na1, Sun Joo Kim1, Sangkyu Lee2. 1. College of Pharmacy, Research Institute of Pharmaceutical Sciences, BK21 Plus KNU Multi-Omics-based Creative Drug Research Team, Kyungpook National University, Daegu, Republic of Korea. 2. College of Pharmacy, Research Institute of Pharmaceutical Sciences, BK21 Plus KNU Multi-Omics-based Creative Drug Research Team, Kyungpook National University, Daegu, Republic of Korea sangkyu@knu.ac.kr.
Abstract
BACKGROUND: Secreted proteins play an important role in promoting cancer (PCa) cell migration and invasion. Proteogenomics helps elucidate the mechanism of diseases, discover therapeutic targets, and generate biomarkers for diagnosis through protein variations. MATERIALS AND METHODS: We carried out mass a spectrometry-based proteomic analysis of the conditioned media (CM) from two human prostate cancer cell lines, belonging to different metastatic sites, to identify potential metastatic and/or aggressive factors. RESULTS: We identified a total of 598 proteins, among which 561 were quantified based on proteomic analysis. Among the quantified proteins, 128 were up-regulated and 83 were down-regulated in DU145/PC3 cells. Six mutant peptides were identified in the CM of prostate cancer cell lines using proteogenomics approach. CONCLUSION: This is the first proteogenomics study in PCa aiming at exploring a new type of metastatic factor, which are mutant peptides, predicting a novel biomarker of metastatic PCa for diagnosis, prognosis and drug targeting. Copyright
BACKGROUND: Secreted proteins play an important role in promoting cancer (PCa) cell migration and invasion. Proteogenomics helps elucidate the mechanism of diseases, discover therapeutic targets, and generate biomarkers for diagnosis through protein variations. MATERIALS AND METHODS: We carried out mass a spectrometry-based proteomic analysis of the conditioned media (CM) from two humanprostate cancer cell lines, belonging to different metastatic sites, to identify potential metastatic and/or aggressive factors. RESULTS: We identified a total of 598 proteins, among which 561 were quantified based on proteomic analysis. Among the quantified proteins, 128 were up-regulated and 83 were down-regulated in DU145/PC3 cells. Six mutant peptides were identified in the CM of prostate cancer cell lines using proteogenomics approach. CONCLUSION: This is the first proteogenomics study in PCa aiming at exploring a new type of metastatic factor, which are mutant peptides, predicting a novel biomarker of metastatic PCa for diagnosis, prognosis and drug targeting. Copyright
Authors: Gloria M Sheynkman; Michael R Shortreed; Anthony J Cesnik; Lloyd M Smith Journal: Annu Rev Anal Chem (Palo Alto Calif) Date: 2016-03-30 Impact factor: 10.745
Authors: Damian Szklarczyk; Andrea Franceschini; Stefan Wyder; Kristoffer Forslund; Davide Heller; Jaime Huerta-Cepas; Milan Simonovic; Alexander Roth; Alberto Santos; Kalliopi P Tsafou; Michael Kuhn; Peer Bork; Lars J Jensen; Christian von Mering Journal: Nucleic Acids Res Date: 2014-10-28 Impact factor: 16.971
Authors: Ju Mi Jeon; Oh Kwang Kwon; Ann-Yae Na; Eun Ji Sung; Il Je Cho; Mirae Kim; Sung Su Yea; So Young Chun; Jun Hyung Lee; Yun-Sok Ha; Tae Gyun Kwon; Sangkyu Lee Journal: PLoS One Date: 2019-08-12 Impact factor: 3.240
Authors: Laurent Dos Santos de Souza; Isabella Porto Carrero Horta; Lana de Souza Rosa; Larissa Gabrielly Barbosa Lima; Jeane Santos da Rosa; Julia Montenegro; Lauriza da Silva Santos; Raquel Bernardo Nana de Castro; Otniel Freitas-Silva; Anderson Junger Teodoro Journal: RSC Adv Date: 2020-08-17 Impact factor: 4.036